KP-692

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameKP-692

Drug Alias NameHInd(RuInd2Cl4)IndH(RuInd2Cl4)IndCRKP-692FFC-14a +[7]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitorsDNA inhibitorsSarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors

TargetsSarcoplasmic/endoplasmic reticulum calcium ATPase 2DNASarcoplasmic/endoplasmic reticulum calcium ATPase 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesDeutsches Krebsforschungszentrum

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversität Wien Deutsches Krebsforschungszentrum

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A